Quantcast

Latest Taiho Pharmaceutical Co. Ltd. Stories

2014-07-23 00:21:22

TOKYO, July 23, 2014 /PRNewswire/ -- - Investment to Foster Early Biotech Start-ups - Taiho Pharmaceutical Co., Ltd. (hereinafter "Taiho"), a fully-fledged oncology pharmaceutical company, announced on July 23 that the company will be investing US$30 million in Remiges BioPharma Fund (hereinafter "Remiges Fund"), a newly formed biotech venture capital fund. Taiho has a long history of developing new therapeutic options to serve the needs of oncologists and cancer patients. Our...

2014-06-28 08:21:00

- TAS-102 demonstrated a statistically significant improvement in overall survival and progression-free survival - BARCELONA, Spain and PRINCETON, N.J., June 28, 2014 /PRNewswire/ -- Taiho Oncology, Inc., a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), announced today detailed findings from its global Phase III RECOURSE trial of TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride), an oral combination anticancer drug. TAS-102 achieved statistically...

2014-05-12 04:21:55

- Chief Commercial Officer, Tim Whitten, to lead commercialization effort - PRINCETON, N.J., May 12, 2014 /PRNewswire/ -- Taiho Oncology, Inc., a division of Taiho Pharmaceutical Co., Ltd. (Japan), today announced the appointment of Tim Whitten to the position of Senior Vice President and Chief Commercial Officer. The appointment of Mr. Whitten represents the initial step in the transition of the company to a more fully integrated clinical development and commercial entity as it...

2014-05-12 04:21:52

- Company Plans to Pursue Regulatory Submissions - TOKYO, May 12, 2014 /PRNewswire/ -- Taiho Pharmaceutical Co., Ltd. (Tokyo, Japan) and its division Taiho Oncology, Inc. (Princeton, N.J.) announced on May 12 results from its global Phase III RECOURSE trial on its oral combination anticancer drug TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride) in refractory metastatic colorectal cancer (mCRC). The RECOURSE trial met its primary endpoint of demonstrating...

2014-03-24 04:22:04

TOKYO, March 24, 2014 /PRNewswire/ -- Taiho Pharmaceutical Co., Ltd. (Tokyo, President: Masayuki Kobayashi) announced on March 24 that it has obtained approval in Japan from the Ministry of Health, Labour and Welfare to manufacture and market the oral combination anticancer drug "Lonsurf(R) combination tablet T15, T20" (nonproprietary names: trifluridine and tipiracil hydrochloride; development code: TAS-102), for the treatment of patients with unresectable advanced or recurrent...

2011-07-22 02:00:00

TOKYO, July 22, 2011 /PRNewswire/ -- Taiho Pharmaceutical Co., Ltd. (HQ: Tokyo, President: Toru Usami) announced on July 22 the results of a randomized, Phase II clinical trial for the novel oral nucleoside antitumor agent TAS-102 under development by the company for metastatic colorectal cancer, at the 9th Annual Meeting of the Japanese Society of Medical Oncology held in Yokohama. (Abstract no. 10428) The trial was a randomized, double-blind, placebo-controlled study with a primary...

2011-03-14 13:54:00

TOKYO, March 14, 2011 /PRNewswire/ -- Taiho Pharmaceutical Co., Ltd., and its parent company, Otsuka Holdings Co., Ltd., announced today that the European Commission (EC) has granted marketing authorization for Teysuno(TM) (S-1), a novel oral anti-cancer agent indicated for the treatment of adults with advanced gastric cancer when given in combination with cisplatin. The authorization is applicable to the 27 Member States and the three European Economic Area (EEA) countries of the European...

2010-12-17 06:41:00

TOKYO, Dec. 17, 2010 /PRNewswire/ -- Taiho Pharmaceutical Co., Ltd., and its parent company, Otsuka Holdings Co., Ltd., announced today that the Committee for Medicinal Products for Human Use (CHMP), a division of the European Medicines Agency (EMA), has issued an opinion recommending approval of Teysuno(TM) (S-1), a novel oral anti-cancer agent, intended for the treatment of advanced gastric cancer in adults when given in combination with cisplatin. The Committee will now recommend that...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.